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Accepted 6 October 2015It has been more than 2 decades since the initial reports
on autologous transplantation for follicular lymphoma [1,2].
These studies were paradigm changing because they pro-
vided the ﬁrst evidence of a curative therapy in this chroni-
cally relapsing illness. However, autologous transplantation
was effective in only a fraction of carefully selected patients
with chemotherapy-sensitive disease. Relapse rates were
high, possibly caused by infusion of occult lymphoma cells
[3]. Therapy-related myelodysplastic syndrome/acute
myeloid leukemia, mostly occurring in the ﬁrst 5 years after
transplant, emerged as a considerable problem, attributable
to conditioning, to prior treatment, and possibly to stem cell
mobilization method [4,5]. Allogeneic transplantation was
soon found to have a very low incidence of disease recur-
rence but also a high early mortality [6].
Three prior studies have compared autologous and allo-
geneic transplantation with consistent conclusions: alloge-
neic transplantation has much higher treatment-related
mortality, regardless of conditioning intensity, but lower rates
of recurrence [7-9]. In this issue, Klyuchnikov et al. [10]
address the same issue again, from a somewhat different
angle: They include only patients with prior exposure to rit-
uximab, only allo-transplants undergoing reduced-intensity
conditioning, and limit their analysis to patients with follic-
ular grades I and II disease. They ﬁnd that allogeneic trans-
plant recipients tend to have more advanced disease, die
much more frequently from complications, and relapse less.
Patients with high lactate dehydrogenase and poor
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Short initial responses, extranodal disease, and chemo-
therapy refractoriness all predict for higher rates of relapse
and/or lower progression-free survival, and older patients
(age > 60) have worse survival. Among long-term survivors,
60% of allogeneic transplant recipients have chronic graft-
versus-host disease (GVHD). The incidence of secondary
malignancies is similar between both groups, with more he-
matologic malignancies in autologous transplants and more
solid tumors in allogeneic transplants. None of these obser-
vations is much different from those in previous studies and
leaves one with a familiar conundrum: the balance of early
toxicity and late relapse.
In an attempt to resolve this issue, the investigators then
focus on patients still in remission at 2 years. A landmark
analysis of this subset shows a lower relapse rate and a better
survival at 10 years in the allogeneic recipients, in part
because of ongoing relapses in autologous transplant pa-
tients. They conclude that compared with autologous
transplantation, reduced-intensity allogeneic transplant
leads to better outcomes in long-term survivors.
This conclusion is unfortunately not very useful for
treatment guidance, because one cannot ahead of time pre-
dict whether a patient will survive in remission for 2 years,
relapse before then, or die of complications. It may also be
ﬂawed. It is likely that the risk proﬁle of the patients sur-
viving in remission at 2 years is quite different and more
favorable from that of the initial study population, because
more of the sickest patients will have died and/or relapsed by
then. Also, because early nonrelapse mortality affects allo-
geneic recipients disproportionately, better survival of the
allogeneic transplant patients beyond 2 years may simply
reﬂect the more favorable initial disease characteristics of
the allogeneic transplant survivors, rather than the impact of
the allogeneic procedure.
The investigators emphasize the continuing risk of
recurrence after autologous transplantation. However,
although there is a continuing risk of disease recurrence
beyond 2 years, the relapse curves of autologous transplant
recipients also ﬂatten out at about 5 years. The data in fact
are consistent with those of others who ﬁnd a cure rate for
autologous transplant, even in the rituximab era, in the range
of 40% to 50% [4,11].
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allogeneic transplant survivors have chronic GVHD. Chronic
GVHD has multiple detrimental effects on quality of life [12]
and results in an ongoing risk of late mortality, extending for
decades after allogeneic transplantation [13,14]. In this re-
gard, the median follow-up of patients in the current study
isdat 5 yearsdrelatively short. More nonrelapse deaths and
ongoing morbidity should be expected in the allogeneic
group as time goes along.
What then do we recommend to those patients who,
despite optimal front-line therapy, suffer an early recurrence
of follicular lymphoma? In such patients there remains a
considerable role for treatment with curative intent, using
either autologous or allogeneic transplantation, and the au-
thors’ observation that results have improved in the past
decade is quite reassuring. But the choice between allogeneic
and autologous transplantation remains far from straight-
forward. The goal of transplant should be to cure as many
patients as possible with a minimum of short- and long-term
sequelae. We continue to recommend autologous trans-
plantation for patients with complete responses to salvage
therapy and who have sufﬁcient stem cells collected. Inter-
estingly, more recent data suggest that for autologous
transplantation, total body irradiation, previously avoided
for fear of therapy-related myelodysplastic syndrome and
used in only 14% of patients in the current series, is more
effective than BEAM and not more toxic, and we have occa-
sionally recommended it [4,15].
We recommend allogeneic transplantation mostly for
those with less than complete responses, those without
adequate stem cell reserve, and those who relapse after
autologous transplantation. To avoid intractable chronic
GVHD, we recommend in vivo T cell depletion [16]. Admit-
tedly, the risk for disease recurrence is slightly increased, but
overall survival similar, and GVHD-free survival likely supe-
rior [17,18].
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
REFERENCES
1. Rohatiner AZS, Price CGA, Amott S, et al. Myeloablative therapy with
autologous bone marrow transplantation as consolidation of remis-
sion in patients with follicular lymphoma. Ann Oncol. 1991;2(Suppl 2):
147.
2. Freedman AS, Ritz J, Neuberg D, et al. Autologous bone marrow
transplantation in 69 patients with a history of low-grade B-cell non-
Hodgkin’s lymphoma. Blood. 1991;77:2524-2529.
3. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of
marrow assessed by PCR before autologous bone marrow trans-plantation for B-cell lymphoma [see comments]. N Engl J Med. 1991;
325:1525-1533.
4. Tarella C, Passera R, Magni M, et al. Risk factors for the development
of secondary malignancy after high-dose chemotherapy and
autograft, with or without rituximab: a 20-year retrospective follow-
up study in patients with lymphoma. J Clin Oncol. 2011;29:814-
824.
5. Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-
dose treatment with autologous haematopoietic progenitor cell sup-
port in 693 patients with follicular lymphoma: an EBMT registry study.
Leukemia. 2007;21:2324-2331.
6. van Besien K, Sobocinski K, Rowlings P, et al. Allogeneic bone
marrow transplantation for low grade lymphoma. Blood. 1998;92:
1832-1836.
7. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autolo-
gous and allogeneic hematopoietic stem cell transplantation for
follicular lymphoma. Blood. 2003;102:3521-3529.
8. Robinson SP, Canals C, Luang JJ, et al. The outcome of reduced intensity
allogeneic stem cell transplantation and autologous stem cell trans-
plantation when performed as a ﬁrst transplant strategy in relapsed
follicular lymphoma: an analysis from the LymphomaWorking Party of
the EBMT. Bone Marrow Transplant. 2013;48:1409-1414.
9. Evens AM, Vanderplas A, LaCasce AS, et al. Stem cell transplantation for
follicular lymphoma relapsed/refractory after prior rituximab: a
comprehensive analysis from the NCCN lymphoma outcomes project.
Cancer. 2013;119:3662-3671.
10. Klyuchnikov E, Bacher U, Kroger NM, et al. Reduced-intensity allog-
rafting as ﬁrst transplantation approach in relapsed/refractory grades
one and two follicular lymphoma provides improved outcomes
in long-term survivors. Biol Blood Marrow Transplant. 2015;21:
2091-2099. [in this issue].
11. Sebban C, Brice P, Delarue R, et al. Impact of rituximab and/or high-
dose therapy with autotransplant at time of relapse in patients
with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26:3614-
3620.
12. Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is
associated with severity of chronic graft-versus-host disease as
measured by NIH criteria: report on baseline data from the Chronic
GVHD Consortium. Blood. 2011;117:4651-4657.
13. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic
hematopoietic cell transplantation and functional status of long-term
survivors: report from the Bone Marrow Transplant Survivor Study.
Blood. 2007;110:3784-3792.
14. Boyiadzis M, Arora M, Klein J, et al. Impact of chronic graft-versus-host
disease on late relapse and survival on 7489 patients after myeloa-
blative allogeneic hematopoietic cell transplantation for leukemia. Clin
Cancer Res. 2015;21:2020-2028.
15. El-Najjar I, Boumendil A, Luan JJ, et al. The impact of total body irra-
diation on the outcome of patients with follicular lymphoma treated
with autologous stem-cell transplantation in the modern era: a
retrospective study of the EBMT Lymphoma Working Party. Ann Oncol.
2014;25:2224-2229.
16. Kenkre VP, Horowitz S, Artz AS, et al. T-cell-depleted allogeneic
transplant without donor leukocyte infusions results in excellent
long-term survival in patients with multiply relapsed Lymphoma.
Predictors for survival after transplant relapse. Leuk Lymphoma. 2011;
52:214-222.
17. Segovia J, van Besien K. Antithymocyte globulin for graft-versus-host
disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015;56:
841-842.
18. Delgado J, Canals C, Attal M, et al. The role of in vivo T-cell depletion on
reduced-intensity conditioning allogeneic stem cell transplantation
from HLA-identical siblings in patients with follicular lymphoma.
Leukemia. 2011;25:551-555.
